11/29/2004 9:22:42 AM ET  


    SWISS MEDICA ANNOUNCES MEDIA CAMPAIGN LAUNCH TO SUPPORT O24(TM) PRODUCT DISTRIBUTION IN
    FIRST U.S. RETAIL CHAIN DRUGSTORE; #2 CHAIN IN 4TH LARGEST US MARKET
     
    Stock Symbol: OTC BB: SWME
    November 29, 2004

    SWISS MEDICA ANNOUNCES MEDIA CAMPAIGN LAUNCH TO SUPPORT O24(TM) PRODUCT DISTRIBUTION IN
    FIRST U.S. RETAIL CHAIN DRUGSTORE; #2 CHAIN IN 4TH LARGEST US MARKET

    Toronto, Canada – Swiss Medica announces the commencement of its multi-media campaign to support sales of
    its flagship product, the O24™ Essential Oil Pain Neutralizer, within the highly regarded 75-store Happy Harry’s
    Discount Drugstore chain, based in Newark, Delaware. The Happy Harry’s chain ranked #2 in the fourth largest
    U.S. chain drug market in 2003, according to Chain Drug Review, and accounted for nearly one-quarter of sales
    in its region.

    Tom Quinn, Vice President of U.S. Operations, announced, “We are delighted to make our U.S. retail debut in
    Happy Harry’s Discount Drug Stores, a retailer that is highly respected in the chain drug industry. We anticipate
    outstanding sales results in their stores based upon the aggressive plan we have in place to generate broad trial
    and repurchase, and Happy Harry’s ability to execute the plan.”

    Happy Harry's Discount Drug Stores is Delaware’s number one pharmacy chain, operating 75 community
    pharmacies in Delaware, Maryland, New Jersey and Pennsylvania. According to an October issue of Chain Drug
    Review, Happy Harry's ranks #7 among U.S. regional pharmacy chain drugstores by dollar volume and #8
    among its competitors by store count. Happy Harry’s easily beat all but one other national chain drugstore in the
    fourth largest U.S. metropolitan market in terms of dollar volume.

    The U.S. media campaign includes multi-media advertising, talk show appearances with physician and surgeon
    Dr. Allan N Fields, and co-sponsorship (with Happy Harry’s) of the Delaware Branch of the Arthritis Foundation’s
    annual 5K Jingle Bell Run. Broad sampling in coordination with the Arthritis Foundation and in Happy Harry’s
    stores will target individuals in approximately ten percent of Delaware households, with those most likely to suffer
    from arthritis pain.

    Locations of the Happy Harry's Discount Drugstore can be found at www.024zone.com. Please click on "Where
    to Buy."


    About Swiss Medica Inc.

    Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. We increase our
    market share through focused distribution strategies in multiple sales channels. Swiss Medica’s mission is to be
    a world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please
    visit our websites at www.swissmedica.com and www.024zone.com

    Swiss Medica’s flagship product, the 024™ Essential Oil Pain Neutralizer, holds US Patent #6,444,238B1. The
    024™ pain relief solution has been used, recommended and praised for its fast-acting and long-lasting benefits
    by healthcare professionals in the United States, Canada and in Europe. O24 is widely available throughout
    Canada in leading pharmacies and natural food stores. It is available in the United States and elsewhere by
    visiting www.024zone.com, for ordering details and store locators.


    Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the
    United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking
    statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close
    transactions being contemplated, risks related to international sales and potential foreign currency exchange
    fluctuations, continued acceptance of Swiss Medica’s products, increased levels of competition, technological
    changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica’s
    periodic reports filed with the United States Securities and Exchange Commission and other regulatory
    authorities.

    Investor Relations Contact:
    David Jones
    1 866 485 4243
    djones@swissmedica.com